Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

These include programmes that employ a novel topoisomerase 1 (TOPO1) inhibitor payload, including Pfizer’s TOPO1-ADC, which targets CEACAM5, and 35C, a next-generation CD30-targeted ADC.

Adcetris is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma. It is designed to remain stable while in the blood stream, but deliver a dose of the ...

An antibody-drug conjugate (ADC) targeting CD30, Brentuximab vedotin, has also been approved by the FDA to specifically target mesenchymal large-cell lymphoma and Hodgkin's lymphoma. Sino ...

CD30, CEACAM5, Nectin 4 and others. The market is expected to be driven by HER-2 (ERBB2) antigen, CD79b target antigen and TROP-2 antigen in mid-long term. It is worth highlighting that the ...